Development of interferon-β as a therapy for multiple sclerosis

Expert Opinion on Emerging Drugs

Volumn 9, Issue 2, 2004, Pages 363-374

  Markowitz, Clyde ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Disease modifying therapy; Drug development; Interferon ; Multiple sclerosis; Neutralising antibodies

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; BETA 2 MICROGLOBULIN; BETA INTERFERON; BETA1A INTERFERON; BIOLOGICAL MARKER; CORTICOTROPIN; CORTISONE; CYSTEINE; GADOLINIUM; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; INTERLEUKIN 12; LIVER ENZYME; METHIONINE; METHYLPREDNISOLONE; NEOPTERIN; NEUTRALIZING ANTIBODY; ORPHAN DRUG; PARACETAMOL; PLACEBO; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2 INTERFERON; RECOMBINANT BETA INTERFERON; RECOMBINANT GAMMA INTERFERON; SERINE; UNINDEXED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANEMIA; ARTHRALGIA; CHILL; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GENE DELETION; GRANULOCYTOPENIA; HAIR LOSS; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INJECTION SITE; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOCYTOPENIA; MALAISE; MENSTRUATION DISORDER; MULTIPLE SCLEROSIS; MYALGIA; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; RECURRENT DISEASE; REMISSION; REVIEW; SCORING SYSTEM; SIDE EFFECT; SWEATING; THROMBOCYTOPENIA;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MICE; MULTIPLE SCLEROSIS; RECOMBINANT PROTEINS;

EID: 10344237524     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.9.2.363     Document Type: Review

References (72)

1. GLASER GH, MERRITT HH: Effects of corticotropin (ACTH) and cortisone on disorders of the nervous system. JAMA (1952) 148:898-904. Classic report on use of immunotherapy for MS exacerbations.
2. DURELLI L, BERGAMINI L: Multiple sclerosis. II. A critical assessment of immunothetapy. Rev. Neurol. (1989) 59:191-201.
3. DURELLI L, COCITO D, RICCIO A et al.: High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations, Neurology (1986) 36:238-243.
4. MILLIGAN NM, NEWCOMBE R, COMPSTON DA: A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J. Neurol. Neurosurg. Psychiatry (1987) 50:511-516.
5. INNES JR, KURLAND LT: Is multiple sclerosis caused by a virus? Am. J. Med. (1952) 12:574-585.
6. KURTZKE JF, HELTBERG A: Multiple sclerosis in the Faroe Islands: an epitome. J. Clin. Epidemiol. (2001) 54:1-22.
7. DALGLEISH AG: Viruses and multiple sclerosis. Acta. Neurol. Scand. (1997) 169(Suppl.):8-15.
8. FAZAKERLEY JK, WALKER R: Virus demyelination. J. Neurovirol. (2003) 9:148-164.
9. ISAACS A, LINDENMANN J: Virus interference. I. The interferon. Proc. R. Soc. Lond. B. Biol. Sci. (1957) 147:258-267. Discovery of IFN.
10. ISAACS A, COX RA, ROTEM Z: Foreign nucleic acids as the stimulus to make interfeton. Lancet (1963) 2:113-116.
11. SEN GC: Viruses and interferons. Ann. Rev. Microbiol. (2001) 55:255-281.
12. STARK GR, KERR IM, WILLIAMS BR, SILVERMAN RH, SCHREIBER RD: How cells respond to interferons. Ann. Rev. Biochem. (1998) 67:227-264.
13. YONG VW, CHABOT S, STUVE O, WILLIAMS G: Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology (1998) 51:682-689.
14. RUNKEL L, MEIER W, PEPINSKY RB et al.: Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β). Pharm. Res. (1998) 15:641-649.
15. GOLDSTEIN D, SIELAFF KM, STORER BE et al.: Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-β serine. J. Natl. Can. Inst. (1989) 81:1061-1068.
16. ser and gamma in humans J. Clin. Invest. (1990) 86:1211-1221.
17. ALAM J, MCALLISTER A, SCARAMUCCI J, JONES W, ROGGEM: Pharmocokinetics and pharmacodynamics of interferon beta-1a (IFNβ-1a) in healthy volunteers after intravenous, subcutaneous or intramuscular administration. Clin. Drug Invest. (1997) 14:35-43.
18. MUNAFO A, TRINCHARD-LUGAN I, NGUYEN TXQ, BURAGLIO M: Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur. J. Neurol. (1998) 5:187-193.
19. JACOBS L, MUNSCHAUER FE: Treatment of multiple sclerosis with interferons. In: Treatment of Mult. Scler.: Trial Designs, Results and Future Perspectives. Rudick RA, Goodkin DE (Eds). Springer, London (1992):223-250.
20. LIBERATI AM, GAROFANI P, DE ANGELIS V et al.: Double-blind randomized Phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-β given intravenously. J. Interferon Res. (1994) 14:61-69.
21. JOHNSON KP, KNOBLER RL, GREENSTEIN JI et al.: Recombinant human beta interferon treatment of relapsing-remitting multiple sclerosis: pilot study results. Neurology (1990) 40(Suppl. 1):261. Abstract 538P.
22. KNOBLER RL, PANITCH HS, BRAHENY SL et al.: Systemic alpha-interferon therapy of multiple sclerosis. Neurology (1984) 34:1273-1279.
23. CAMENGA DL, JOHNSON KP, ALTER M et al: Systemic recombinant α-2 interferon therapy in relapsing multiple sclerosis. Arch. Neurol. (1986) 43:1239-1246.
24. AUSTIMS RESEARCH GROUP: Interferon-α and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. J. Neurol. Neurosurg. Psychiatry (1989) 52:566-574.
25. DURELLI L, BONGIOANNI MR, CAVALLO R et al.: Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology (1994) 44:406-413.
26. PANITCH HS, HIRSCH RL, SCHINDLER J, JOHNSON KP: Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology (1987) 37:1097-1102.
27. VERVERKEN D, CARTON H, BILLAU A: Intrathecal administration of interferon in MS patients. In: Humoral Immunity in Neurological Disease. Karcher D, Lowenthal A, Strosberg AD (Eds.) Plenum, New York (1979):625-627.
28. HUBER M, BAMBORSCHKE S, ASSHEUER J, HEISS WD: Intravenous natural beta interferon treatment of chronic exacerbating-remitting multiple sclerosis: clinical response and MRI/CSF findings. J. Neurol. (1988) 235:171-173.
29. BAUMHEFNER RW, TOURELLOTTE WW, SYNDULKO K: Multiple sclerosis: effect of intravenous natural beta-interferon on clinical neurofunction, magnetic resonance imaging plaque burden, intra-blood-brain barrier IgG synthesis and cerebrospinal fluid immunology and visual evoked potentials. Ann. Neurol. (1987) 22:171. Abstract P207.
30. JACOBS L, O'MALLEY J, FREEMAN A, EKES R: Intrathecal interferon reduces exacerbations of multiple sclerosis. Science (1981) 214:1026-1028.
31. JACOBS L, O'MALLEY J, FREEMAN A, MURAWSKI J, EKES R: Intrathecal interferon in multiple sclerosis. Arch. Neurol. (1982) 39:609-615.
32. JACOBS L, O'MALLEY JA, FREEMAN A, EKES R, REESE PA: Intrathecal interferon in the treatment of multiple sclerosis. Patient follow-up. Arch. Neurol. (1985) 42:841-847.
33. JACOBS L, SALAZAR AM, HERNDON R et al.: Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis. Lancet (1986) 2:1411-1413.
34. THE IFNB MULTIPLE SCLEROSIS STUDY GROUP: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology (1993) 43:655-661. Phase III clinical trial.
35. PATY DW, LI DK: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. THE UBC MS/ MRI Study Group, the IFNB Mult. Scler. Study Group. Neurology (1993) 43:662-667.
36. JACOBS LD, COOKFAIR DL, RUDICK RA et al.: Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. (1996) 39:285-294. Phase III clinical trial.
37. FDA: Summary basis for approval, interferon beta 1a. (1996) BLA 103628.
38. PRISMS (PREVENTION OF RELAPSES AND DISABILITY BY INTERFERON β-1A SUBCUTANEOUSLY IN MULTIPLE SCLEROSIS) STUDY GROUP: Randomized double-blind placebo-controlled study of Interferon β-1a in relapsing/remitting multiple sclerosis. Lancet (1998) 352:1498-1504. Phase III clinical trial.
39. LI DK, PATY DW: Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis. The UBC MS/MRI Analysis Research Group, the PRISMS Study Group. Ann. Neurol. (1999) 46:197-206.
40. FDA: Comparative study of Rebif to Avonex and orphan exclusivity. (2002) BLA 103780.
41. KAPPOS L, POLMAN C, POZZILLI C, THOMPSONA, BECKMANN K, DAHLKE F: Final analysis of the European multicenter trial on IFNbeta-1b in secondary- progressive MS. European Study Group in Interferon Beta-1b in Secondary-Progressive MS. Neurology (2001) 57:1969-1975.
42. PANTICH H: Clinical trials in secondary progressive MS. Assessing response to therapy. Int. J. MS Care (2000) Sept (Suppl.):5.
43. SECONDARY PROGRESSIVE EFFICACY CLINICAL TRIAL OF RECOMBINANT INTERFERON-BETA-1A IN MS (SPECTRIMS) STUDY GROUP: Randomized controlled trial of interferon- beta-1a in secondary progressive MS: clinical results. Neurology (2001) 56:1496-1504.
44. ANDERSEN O, ELOVAARA I, FARKKILAM et al.: Multicentre, randomized, double blind, placebo controlled, Phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis, J. Neurol. Neurosurg. Psychiatry (2004) 75:706-710.
45. COHEN JA, CUTTER GR, FISCHER JS et al.: Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. IMPACT investigators. Neurology (2002) 59:679-687.
46. MONTALBAN X: Overview of European pilot study of interferon beta-1b in primary progressive multiple sclerosis. Mult. Scler. (2004) (Suppl. 1):S62.
47. LEARY SM, MILLER DH, STEVENSON VL, BREX P, CHARD DT, THOMPSON AJ: Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology (2003) 60(1):44-51.
48. JACOBS LD, BECK RW, SIMON JH et al.: Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. (2000) 343:898-904.
49. COMI G, FILIPPI M, BARKHOF F et al.: Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Early Treatment of Multiple Sclerosis Study Group. Lancet (2001) 357:1576-1582.
50. KATZ D, TAUBENBERGER JK, CANNELLA B, MCFARLIN DE, RAINE CS, MCFARLAND HF: Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann. Neurol. (1993) 34:661-669.
51. SIMON JH: Contrast enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis. J. Magn. Reson. Imaging (1997) 7:29-37.
52. SMITH ME, STONE LA, ALBERT PS et al.: Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglurnine-enhancing magnetic resonance imaging lesions. Ann. Neurol. (1993) 33:480-489.
53. KHOURY SJ, GUTTMANN CR, ORAV EJ et al.: Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology (1994) 44:2120-2124.
54. TUBRIDY N, COLES AJ, MOLYNEUX P et al.: Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features. Brain (1998) 121:225-231.
55. 1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology (1996) 47:1469-1476.
56. VAN WAESBERGHE JH, CASTELIJNS JA, SCHELTENS P et al.: Comparison of four potential MR parameters for severe tissue destraction in multiple sclerosis lesions. Magn. Reson. Imaging (1997) 15:155-162.
57. VAN WALDERVEEN MA, KAMPHORST W, SCHELTENS P et al.: Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology (1998) 50:1282-1288.
58. PANITCH H, GOODIN DS, FRANCIS G et al.: (Evidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group. Randomized, comparative study of Interferon β-1a treatment regimens in MS. The EVIDENCE Trial. Neurology (2002) 59:1496-1506.
59. BERTOLOTTO A, MALUCCHI S, SALA A et al.: Differential effects of three interferon betas on neutralizing antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J. Neurol. Neurosurg. Psych. (2002) 73:148-153.
60. THE IFNB MULTIPLE SCLEROSIS STUDY GROUP, THE UNIVERSITY OF BRITISH COLUMBIA MS/MRI ANALYSIS GROUP: Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology (1996) 47:889-894.
61. PRISMS (PREVENTION OF RELAPSES AND DISABILITY BY INTERFERON β-1A SUBCUTANEOUSLY IN MULTIPLE SCLEROSIS) STUDY GROUP AND THE UNIVERSITY OF BRITISH COLUMBIA MS/MRI ANALYSIS GROUP. PRISMS 4: Long-term efficacy of interferon β-1a in relapsing MS. Neurology (2001) 56:1628-1636.
62. PETKAU AJ, WHITE RA, EBERS GC et al.: Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult. Scler. (2004) 10:126-138.
63. SORENSEN PS, ROSS C, CLEMMESEN KW et al.: Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet (2003) 362:1184-1191.
64. MALUCCHI S, SALA A, GILLI F et al.: Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology (2004) 62:2031-2037.
65. GILLI F, BERTOLOTTO A, SALA A et al.: Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. Brain (2004) 127:259-268.
66. RICE GPA, PASZNER B, OGER J et al.: The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b. Neurology (1999) 52:1277-1278.
67. GAOTH N: Multiple sclerosis in children. Brain Devel. (2003) 25:229-232.
68. POZZILLI C, ANTONINI G, BAGNATO F et al.: Monthly corticosteroids decrease neutralizing antibodies to IFNβ1b: a randomized trial in multiple sclerosis. J. Neurol. (2002) 249:50-56.
69. VAN DER FLIER WM, VAN DEN HEUVEL DM, WEVERLING-RIJNSBURGER AW et al.: Magnetization transfer imaging in normal aging, mild cognitive impairment, and Alzheimer's disease. Ann. Neurol. (2002) 52:62-67.
70. TRABOULSEE A, DEHMESHKI J, PETERS KR et al.: Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities. Mult. Scler. (2003) 9:566-573.
71. LOSSEFF NA, WANG L, LAI HM et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain (1996) 119:2009-2019.
72. RUDICK RA, FISHER E, LEE JC, SIMON J, JACOBS L: Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remirting MS. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology (1999) 53:1698-1704.